Premium
Novel Form of Curcumin Improves Endothelial Function in Young, Healthy Individuals
Author(s) -
Oliver Jonathan Michael,
Caldwell Aaron,
Sanders Elizabeth,
Rowlands David,
Purpura Martin,
Jäger Ralf
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.lb340
Subject(s) - curcumin , placebo , medicine , brachial artery , endothelial dysfunction , analysis of variance , pharmacology , pathology , alternative medicine , blood pressure
It is known that endothelial dysfunction (ED) may increase the risk of cardiovascular disease (CVD). ED can be measured as a decreased flow‐mediated dilation (FMD) response, using occlusion and subsequent dilation response of the brachial artery. Increased levels of inflammatory molecules contribute to ED, and increase CVD. Curcumin, a highly pleiotropic molecule, interacts with multiple inflammatory pathways primarily by inhibiting the IκB Kinase (IKK) signaling complex thereby preventing the activation of nuclear factor‐kappa B (NF‐κB). However, poor solubility and rapid metabolism may limit benefits. CurcuWIN®, a novel curcumin formulation containing 20% curcuminoids (CUR), resulted in 45.9 fold greater absorption over standard curcumin. This current study sought to examine the effect of differing doses of a novel form of curcumin on FMD. Fifty‐nine moderately trained men (n=30; 21±2 years; 173.8±20.0 cm; 79.4±11.0 kg) and women (n=29; 21±2 years; 164.9±6.5 cm; 60.1±8.0 kg) were randomly assigned to ingest 50 mg CUR (in the form of 250 mg CurcuWIN®), 200 mg CUR (in the form of 1000 mg CurcuWIN®), or placebo (PLA) for eight weeks in a double‐blind, randomized, placebo controlled parallel design. ANOVA and paired t‐tests were used to examine differences followed by magnitude based inference. Subsequently, a subset analyses was performed on subjects with a baseline FMD ≤7%. An improvement of magnitude (Effect size [ES] = 0.67) of FMD was observed in those receiving 200mg CUR (Pre, 7.6±3.2%; Post, ↑10.4±3.5%; p=0.011). FMD improvement (↑2.8±3.3%) was beneficial compared to PLA (↓−0.8±5.4%; p=0.020). No change was observed in those receiving 50MG CUR (Pre, 8.2±3.3%; Post, ↑9.1±2.7%; p=0.405). Twenty‐five (PLA, n=8; 50MG, n=7; 200MG, n=10) had baseline FMD <7%. Supplementation resulted in improvement of very large magnitude (ES > 2.0) in those receiving 50MG (Pre, 4.9±1.4%; Post, 8.1±1.6%; p=0.029) and 200MG (Pre, 5.2±1.1%; Post, ↑8.9±3.5%; p=0.005). These data demonstrate 200mg CUR improves FMD (endothelial function) in healthy young subjects. Further, in those with baseline FMD ≤7% FMD (at risk) 50mg CUR and 200mg CUR improves endothelial function. Given every 1% increase in FMD reduces cardiovascular disease risk by 9–17%; further research in clinical populations is recommended to clarify the true nature of the effect and potential mechanism(s). Support or Funding Information OmniActive Health Technologies Ltd. Mumbai, India